KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Current Assets (2016 - 2025)

Historic Current Assets for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $1.1 billion.

  • Acadia Pharmaceuticals' Current Assets rose 3655.26% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 3655.26%. This contributed to the annual value of $938.3 million for FY2024, which is 5229.34% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Current Assets is $1.1 billion, which was up 3655.26% from $960.6 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Current Assets registered a high of $1.1 billion during Q3 2025, and its lowest value of $492.6 million during Q2 2023.
  • For the 5-year period, Acadia Pharmaceuticals' Current Assets averaged around $675.4 million, with its median value being $640.9 million (2021).
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Current Assets plummeted by 1954.96% in 2022, and later soared by 5791.89% in 2024.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Current Assets stood at $617.8 million in 2021, then fell by 17.79% to $507.9 million in 2022, then increased by 21.3% to $616.1 million in 2023, then skyrocketed by 52.29% to $938.3 million in 2024, then grew by 14.72% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $960.6 million for Q2 2025, and $870.9 million during Q1 2025.